Compare · ENOV vs EW
ENOV vs EW
Side-by-side comparison of Enovis Corporation (ENOV) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENOV and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $48.14B, about 35.8x ENOV ($1.34B).
- Over the past year, ENOV is down 32.3% and EW is up 11.1% - EW leads by 43.4 points.
- Both names hit the wire about 6 times in the past 4 weeks.
- EW has more recent analyst coverage (25 ratings vs 19 for ENOV).
- Company
- Enovis Corporation
- Edwards Lifesciences Corporation
- Price
- $23.43+4.25%
- $83.53+2.85%
- Market cap
- $1.34B
- $48.14B
- 1M return
- +3.01%
- +4.31%
- 1Y return
- -32.27%
- +11.11%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 6
- 6
- Recent ratings
- 19
- 25
Enovis Corporation
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest ENOV
- SEC Form SCHEDULE 13G filed by Enovis Corporation
- William Blair resumed coverage on Enovis Corporation
- SEC Form 3 filed by new insider Singleton Laura Lee
- Enovis to Host First Quarter 2026 Results Conference Call on May 7th
- SEC Form DEFA14A filed by Enovis Corporation
- SEC Form DEF 14A filed by Enovis Corporation
- SEC Form 4 filed by Ortiz Christine
- Amendment: SEC Form SCHEDULE 13G/A filed by Enovis Corporation
- Chief Administrative Officer Engert Oliver bought $23,740 worth of shares (1,000 units at $23.74), increasing direct ownership by 2% to 48,640 units (SEC Form 4)
- Chief Administrative Officer Engert Oliver bought $23,930 worth of shares (1,000 units at $23.93), increasing direct ownership by 2% to 47,640 units (SEC Form 4)
Latest EW
- Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports First Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Lippis Daniel J.
- SEC Form 4 filed by Bobo Donald E Jr
- Edwards Lifesciences upgraded by Wolfe Research with a new price target
- Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
- Amendment: SEC Form SCHEDULE 13G/A filed by Edwards Lifesciences Corporation